(Solifenacin tartrate) - 药物靶点：M3 receptor_专利_临床

概要

基本信息

药物类型

小分子化药

别名

HIP-1503

靶点

M3 receptor

作用机制

M3 receptor激动剂(毒蕈碱型乙酰胆碱受体M3激动剂)

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

膀胱过度活动症

原研机构

Hanmi Pharmaceutical Co., Ltd.

在研机构-

非在研机构

Hanmi Pharmaceutical Co., Ltd.

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

结构

分子式C27H32N2O8

InChIKeyKTNRTEKPBRTUKA-DWERDEDHSA-N

CAS号1035547-81-9

关联

15

项与 Solifenacin tartrate 相关的临床试验

IRCT20160606028304N2 / Completed临床4期

Efficacy of Solifenacin and trospium chloride on neurogenic bladder after stroke: a multicentric three arms placebo-controlled trial

开始日期2021-07-01

申办/合作机构

Tabriz University of Medical Sciences

NCT05040984 / RecruitingN/AIIT

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

开始日期2021-04-30

申办/合作机构

医疗财团法人徐元智先生医药基金会亚东纪念医院

IRCT20151123025202N4 / Recruiting临床3期

Comparing effect of cutaneous posterior tibial nerve stimulation with medical treatment with Solifenacin in patients with overactive bladder

开始日期2019-11-21

申办/合作机构

Hamedan University of Medical Sciences

100 项与 Solifenacin tartrate 相关的临床结果

登录后查看更多信息

100 项与 Solifenacin tartrate 相关的转化医学

登录后查看更多信息

100 项与 Solifenacin tartrate 相关的专利（医药）

登录后查看更多信息

757

项与 Solifenacin tartrate 相关的文献（医药）

2024-03-01·Journal of chemical neuroanatomy

Solifenacin promotes remyelination in cuprizone mouse model by inhibiting the Wnt/β-catenin signaling pathway

Article

作者: Yao, Ruiqin ; Liu, Yaping ; Liu, Jinfeng ; Chen, Fei ; Meng, Qiqi ; Song, Xueli ; Yan, Weixing ; Xu, Xinqi ; Dong, Fuxing

Demyelinating diseases are a type of neurological disorder characterized by the damage to the myelin sheath in the central nervous system. Promoting the proliferation and differentiation of oligodendrocyte precursor cells (OPCs) is crucial for treatment. Non-selective muscarinic receptor (MR) antagonists have been shown to improve remyelination in rodent models, although the mechanisms are still unclear. In this study, we treated cuprizone (CPZ)-induced demyelination mouse model with different concentrations of Solifenacin (Sol), a selective M3 receptor antagonist, to determine the optimal concentration for promoting remyelination. Behavioral tests and Luxol fast blue (LFB) staining were used to observe the extent of remyelination, while immunofluorescence was used to measure the expression levels of myelin-related proteins, including myelin basic protein (MBP) and platelet-derived growth factor receptor alpha (PDGFR-α). Western blot analysis was employed to analyze the expression levels of molecules associated with the Wnt/β-catenin signaling pathway. The results showed that Sol treatment significantly promoted myelin regeneration and OPCs differentiation in CPZ-induced demyelination mouse model. Additionally, Sol treatment inhibited the Wnt/β-catenin signaling pathway and reversed the effects of CPZ on OPCs differentiation. In conclusion, Sol may promote the differentiation of OPCs by inhibiting the Wnt/β-catenin signaling pathway, making it a potential therapeutic option for central nervous system demyelinating diseases.

2024-02-01·Chirality

Separation and simultaneous estimation of enantiomers and Diastereomers of muscarinic receptor antagonist Solifenacin using stability‐indicating Normal‐phase HPLC technique with chiral stationary phase amylose tris‐(3,5‐dimethylphenylcarbamate)

Article

作者: Venkatanarayana, Muvvala ; Chinnakadoori, Sanjeeva R ; Vadagam, Niroja ; Haridasyam, Sharath Babu ; Lakka, Narasimha S

Abstract:

The R,S‐enantiomer impurity and diastereomer impurities (S,S‐isomer and R,R‐isomer) of the solifenacin (S,R‐enantiomer) were effectively separated and quantified simultaneously utilizing normal‐phase high‐performance liquid chromatography with a chiral stationary phase consisting of amylose tris (3,5‐dimethylphenylcarbamate) coated on silica‐gel (Chiralpak, AD‐H). The enantiomeric and stereo‐selective separation was achieved within a run time of 35 minutes using a mobile phase of ‘n‐hexane, ethanol, and diethylamine’ in an isocratic elution mode with a detection wavelength of 220 nm. The validation attributes assessed were accuracy (which showed excellent recoveries between 97.5% and 100.4%) and linearity (which was proven in the range of 0.081–1.275 μg.mL−1, with a linear regression of 0.999). The stress testing experiments proved that the developed methodology by the HPLC technique has stability‐indicating characteristics, as all closely eluting peak pairs were separated well with a resolution of 2.3 and without any interference. The proposed methodology was highly efficient in separating and simultaneously determining the chiral impurities (enantiomers and diastereomers) of the solifenacin in the release and stability sample analyses of drug substances and tablets in pharmaceutical formulations.

2024-02-01·Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy

Fluorimetric study on a novel FDA-approved combination used for the treatment of overactive bladder syndrome in different matrices

Article

作者: Hasan, Mohamed A ; Badrawy, Mohamed ; Mohamed, Ahmed R ; Nour, Israa M

For the first time, two spectrofluorimetric techniques were created for the concurrent determination of mirabegron (MBN) and solifenacin (SOL) in different matrices. This novel combination recently received FDA approval to treat overactive bladder syndrome and was marketed under the brand name Mirago^TMS₂₅. SOL has a native fluorescence and can be estimated directly in the presence of MBN without any interference at 290 nm after excitation at 230 nm. In contrast to SOL, MBN is a weak fluorescent substance that requires the use of a fluorogenic reagent (like NBD-Cl) to be measured simultaneously with SOL in their mixtures. So, we reacted MBN with NBD-Cl to yield a yellow-colored fluorophore that could be estimated at 546 nm after excitation at 471 nm without any preliminary separation or interference from SOL. All experimental conditions of the applied methods were tested and enhanced for the best results. The applied fluorimetric methods succeeded in determining both drugs in nanograms, making them applicable in biological fluids like human plasma. The linearity ranges of SOL and MBN were found to be 5-250 ng/mL and 50-600 ng/mL, respectively. The LOD values were 0.96 ng/mL and 5.09 ng/mL for SOL and MBN, in order. Excellent results were attained for both drugs during their analysis in spiked plasma samples employing the applied fluorimetric methods, confirming their suitability for use in real human plasma samples and paving the way for further bioequivalence studies on both drugs.

1

项与 Solifenacin tartrate 相关的新闻（医药）

2022-12-05

·Business Wire

$4.2 Billion Overactive Bladder Treatment (OAB) Markets - Global Forecasts to 2027: Growing R&D Investments and the Launch of Novel Therapies in the Coming Years - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Overactive Bladder Treatment (OAB) Market by Drug type ( Anticholinergic (Solifenacin, Oxybutynin, Tolterodine, Darifenacin), Mirabegron), Botox, Neuromodulation, Disease Type (Idopathic OAB and Neurogenic OAB) and Region - Global Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering. The global overactive bladder treatment market is projected to reach USD 4.2 billion by 2027 from USD 3.5 billion in 2022, at a CAGR of 3.6% Rising prevalence of overactive bladder across the globe coupled with rising awareness about treatment options available is driving the growth of the market. Additionally, use of neuromodulation techniques for the treatment of OAB is further expected to have a significant positive impact. The adoption of novel treatments and the launch of new drugs for OAB treatment are also likely to support market growth in the coming years. Mirabegron segment dominates the overactive bladder (OAB) treatment market in 2021. Based on type, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, neuromodulation, and other treatments. Mirabegron held a dominant share of the market in 2021, owing to the lesser side-effects associated with this drug compared to other drug classes available in the market. Furthermore, neuromodulation segment is expected to grow at faster pace owing to launch of new SNM & PTNS for OAB in market. The idiopathic overactive bladder segment will witness the highest growth in overactive bladder treatment market during the forecast period. Based on disease type, the overactive bladder treatment market is segmented into idiopathic overactive bladder and neurogenic overactive bladder. The idiopathic overactive bladder segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders and increased use of drugs for the treatment. North America held dominant share in 2021. In 2021, North America accounted for the major share in the OAB treatment market. North America holds majority of the key market players leading to maturity of OAB treatment market in this region. Furthermore, favorable reimbursement policies in US is one of the leading factor projecting market growth in North America. Competitive landscape The prominent players in this market are Astellas Pharma Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Pfizer Inc. (US), Medtronic Plc (Ireland), AbbVie Inc. (US), Viatris Inc. (US), Hisamitsu Pharmaceutical Co., Inc. (Japan), Johnson & Johnson Services, Inc. (US), and Endo Pharmaceuticals Inc. (Ireland). Market Dynamics Market Drivers Rising Prevalence of Overactive Bladder Syndrome Rapidly Aging Population and Subsequent Rise in Incidence of Diseases Characterized by Oab Development and Use of Innovative Intravesical Therapies Growing R&D Investments and the Launch of Novel Therapies in the Coming Years Market Restraints Frequent Product Recalls Increased Side-Effects of Anticholinergic Drugs Market Opportunities Novel Treatments, Robust Pipelines, and Patent Cliff of Certain Drugs Market Challenges Social Stigma and Lack of Awareness About OAB Companies mentioned: Abbvie Inc Ajanta Pharma Altherx Pharmaceuticals Amneal Pharmaceuticals LLC Apotex Inc Astellas Pharma Inc Bayer Ag Endo Pharmaceuticals Inc Glenmark Granules India Limited Hisamitsu Pharmaceutical Co Inc Hugel, Inc Intas Pharmaceuticals Ltd Johnson & Johnson Services, Inc Laborie Lupin Macleods Pharmaceuticals Ltd Medtronic Medytox Pfizer Inc Sun Pharmaceutical Industries Ltd Taiho Pharmaceutical Co Ltd Teva Pharmaceutical Industries Ltd Urovant Sciences Viatris Inc For more information about this report visit https://www.researchandmarkets.com/r/2n1a4y About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

100 项与 Solifenacin tartrate 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Solifenacin tartrate	-	DB01591

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
膀胱过度活动症	临床1期	-	Hanmi Pharmaceutical Co., Ltd.	2016-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01565707 (Pubmed \| Eur Urol) 人工标引	临床3期	膀胱过度活动症	-	Solifenacin	壓顧衊窪製蓋鬱齋淵淵(衊鬱鏇餘膚鑰鹹顧願衊): difference = 12.1 (95% CI, 0.2 ~ 24.0), P-Value = 0.046 更多	积极	2017-03-01
				Placebo
AUA2014	N/A	前列腺增生症	155	Solifenacin 5 mg/day	壓製獵簾壓壓獵構廠夢(顧積壓鹹遞網餘窪襯餘) = 1 case had blurred vision 蓋鹽淵構憲夢積壓淵積 (獵艱製鏇鏇網憲繭膚簾 ) 更多	-	2014-04-01
				Mirabegron 50 mg/day
1960 (AUA2011)	N/A	膀胱过度活动症	92	Solifenacin 5mg	襯襯鏇獵願夢範顧願簾(觸衊鬱鏇鏇構窪鏇膚艱) = 糧衊顧襯壓艱膚齋鑰齋窪淵鏇鑰遞積鏇鑰築蓋 (艱鏇壓範鬱網膚糧蓋鑰 )	-	2011-04-01
				Solifenacin 5mg + Aclatonium Napadisilate 150mg	襯襯鏇獵願夢範顧願簾(觸衊鬱鏇鏇構窪鏇膚艱) = 鬱窪膚衊襯膚窪鬱醖齋窪淵鏇鑰遞積鏇鑰築蓋 (艱鏇壓範鬱網膚糧蓋鑰 )
Pubmed \| Clin Ther	N/A	-	441	Solifenacin	鹹廠顧獵鏇積選構壓範(衊簾蓋簾廠簾窪膚衊顧) = 襯艱壓憲簾獵築繭獵齋鹹製夢網築選壓願蓋鬱 (獵製齋構積壓憲夢觸膚 ) 更多	-	2008-10-01
STAR study (Pubmed \| Eur Urol)	N/A	-	-	Solifenacin 5 mg	觸衊範願遞衊壓鏇膚鹽(獵餘醖繭廠選築淵蓋糧) = 廠鏇鬱願繭糧窪淵夢壓糧齋襯壓遞襯憲鹽鑰築 (範憲願憲膚遞膚蓋襯選 )	积极	2007-10-01
				Tolterodine ER 4 mg	觸衊範願遞衊壓鏇膚鹽(獵餘醖繭廠選築淵蓋糧) = 淵膚鑰範壓膚鏇繭選願糧齋襯壓遞襯憲鹽鑰築 (範憲願憲膚遞膚蓋襯選 )